[HTML][HTML] Recent advances in drug discovery for triple-negative breast cancer treatment
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
[HTML][HTML] Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani, C Sette… - Molecules, 2023 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu… - Molecules (Basel …, 2023 - pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani, C Sette… - …, 2023 - search.proquest.com
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
[PDF][PDF] Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani… - …, 2023 - pdfs.semanticscholar.org
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.
D Masci, C Naro, M Puxeddu, A Urbani, C Sette… - …, 2023 - search.ebscohost.com
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
[PDF][PDF] Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani, C Sette… - Molecules, 2023 - iris.uniroma1.it
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani, C Sette… - …, 2023 - publicatt.unicatt.it
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
D Masci, C Naro, M Puxeddu, A Urbani… - Molecules (Basel …, 2023 - europepmc.org
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.
D Masci, C Naro, M Puxeddu, A Urbani… - Molecules (Basel …, 2023 - europepmc.org
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …